Registry for Atypical Femur Fractures in Quebec
Quebec Registry for Atypical Femur Fractures
This study looks at older adults in Quebec who have had unusual thigh bone fractures to see how certain medications and bone structure might affect their risk of these injuries.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 45 Years and up |
| Sex | All |
| Sponsor | McGill University Academic / other |
| Drugs / interventions | denosumab |
| Locations | 1 site (Montreal, Quebec) |
| Trial ID | NCT02150850 on ClinicalTrials.gov |
What this trial studies
This project aims to characterize clinical, biomechanical, radiological, and genetic predictors of atypical femur fractures (AFF) in patients aged 45 and older from Quebec. It focuses on individuals who have sustained an AFF, particularly in relation to the use of bisphosphonates and denosumab therapy. The study will analyze the unique geometrical variations of the femur in these patients, hypothesizing that specific mechanical forces contribute to the occurrence of these fractures. By gathering comprehensive data, the study seeks to enhance understanding of AFF and its risk factors.
Who should consider this trial
Good fit: Ideal candidates are men and women aged 45 and older from Quebec who have sustained an atypical femur fracture.
Not a fit: Patients with disorders of bone metabolism other than osteoporosis or those with active cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this research could lead to improved identification and management of patients at risk for atypical femur fractures.
How similar studies have performed: While the study focuses on a specific subset of fractures, similar observational studies have provided valuable insights into fracture risks associated with osteoporosis treatments.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * age 45 years and older * men and women from Quebec who sustain (or have sustained) an AFF (complete or incomplete), as defined by the American Society of Bone and mineral Research (ASBMR) International Task Force on AFFs (Shane E et al J Bone Miner Res 2014;29:1-24) Exclusion Criteria: * inability to consent * disorders of bone metabolism other than osteoporosis * active cancer * life expectancy less than 12 months.
Where this trial is running
Montreal, Quebec
- Montreal General Hospital — Montreal, Quebec, Canada (Recruiting)
Study contacts
- Principal investigator: Suzanne Morin, MD MSc — McGill University Health Centre/Research Institute of the McGill University Health Centre
- Study coordinator: Michelle Wall, MSc.
- Email: michelle.wall@mail.mcgill.ca
- Phone: 514-934-1934
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.